28 results on '"Sarcev T"'
Search Results
2. EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
- Author
-
Milovancev A, Stojsic V, Zaric B, Kovacevic T, Sarcev T, Perin B, Zarogoulidis K, Tsirgogianni K, Freitag L, Darwiche K, Tsavlis D, Zissimopoulos A, Stratakos G, and Zarogoulidis P
- Subjects
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,respiratory tract diseases - Abstract
Aleksandar Milovancev,1 Vladimir Stojsic,1 Bojan Zaric,1 Tomi Kovacevic,1 Tatjana Sarcev,1 Branislav Perin,1 Konstantinos Zarogoulidis,2 Katerina Tsirgogianni,2 Lutz Freitag,3 Kaid Darwiche,3 Drosos Tsavlis,2 Athanasios Zissimopoulos,4 Grigoris Stratakos,5 Paul Zarogoulidis2 1Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, Faculty of Medicine, University of Novi Sad, Serbia; 2Pulmonary Department-Oncology Unit, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Department of Interventional Pneumology, Ruhrlandklinik, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 4Nuclear Medicine Department, Democritus University of Thrace, Alexandroupolis, 5Department of Interventional Pneumology, “Sotiria” Hospital of Chest Diseases, Athens, Greece Abstract: Epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs) brought a significant revolution in the treatment of non-small-cell lung cancer (NSCLC). In a short period of time, EGFR-TKIs became the standard of treatment for mutation-positive, advanced stage non-squamous NSCLC. In recent years, second- and third-generation EGFR-TKIs are emerging, further widening the clinical use. However, the question of EGFR-TKIs efficiency in the treatment of early stage NSCLC still remains open. Early clinical trials failed to approve the use of EGFR-TKIs in adjuvant setting. The majority of these early trials were performed in unselected NSCLC populations and without standardized biomarker identification. One should certainly not rely solely on these results and dismiss the use of EGFR-TKIs as adjuvant therapy. Many important questions are still unanswered. Most important issues such as stage heterogeneity (IA–IIIA), timing (after or concomitantly with chemotherapy), and type of administration (monotherapy or combination) need to be answered in near future. Adjuvant TKIs in the treatment of lung cancer might offer significant number of advancements. Having in mind the significant duration of response observed in advance disease setting, there could be place for prolongation of response in adjuvant setting potentially, leading to improvement in survival. TKIs could offer less-toxic adjuvant treatment with better efficiency than chemotherapy. However, there is a chronic lack of randomized controlled trials in this field, leading to inability to draw any scientifically sound conclusion with regard to the adjuvant treatment. For now, the use of EGFR-TKIs outside clinical trial setting is not recommended. The purpose of this review is to evaluate current and available data. Keywords: adjuvant chemotherapy, EGFR-TKIs, erlotinib, gefitinib, NSCLC
- Published
- 2015
3. Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in eastern european caucasian population
- Author
-
Zaric, B. Stojsic, V. Panjkovic, M. Tegeltija, D. Stepanov, V. Kovacevic, T. Sarcev, T. Radosavljevic, D. Milovancev, A. Adamidis, V. Zarogoulidis, P. Hohenforst-Schmidt, W. Trakada, G. Rapti, A. Perin, B.
- Subjects
hemic and lymphatic diseases - Abstract
Introduction: The incidence of echinoderm microtubule-associated protein-like4-anaplastic lymphoma kinase (EML4-ALK) mutation among surgically treated patients with adenocarcinoma of the lung of the Eastern European ethnicity is underreported. The aim of this trial was the determination of EML4-ALK mutation frequency in investigated population, and the evaluation of correlations between lung adenocarcinoma subtype and clinical characteristics with mutation status. Patients and methods: This was a prospective trial which included 195 patients with adenocarcinoma of the lung who underwent surgical treatment. ALK mutation screening was performed by immunohistochemistry (IHC). IHC scores of 2+ and 3+ were regarded as positive. Confirmatory FISH was performed in all IHC positive and in 2:1 ratio in negative patients. Results: Overall ALK mutation rate established by IHC was 6.2%, while FISH confirmed rate of 5.1%. The FISH confirmed ALK positivity in 7.6% Hungarians, 5.5% Serbians, and 6.6% Slovakians. Acinar subtype of adenocarcinoma of the lung was significantly (p=0.02) related to EML4-ALK positive mutation status. Most of the patients were males (56.9%), smokers (50.8%), or former smokers (28.7%) with acinar (55.4%) or solid (35.9%) adenocarcinoma of the lung. Sensitivity and specificity of IHC were 100% and 98.9% respectively. Conclusions: ALK mutation rate in surgically treated patients with adenocarcinoma of the lung was found to be 6.2% by IHC and 5.1% by FISH. Acinar subtype of the adenocarcinoma of the lung was significantly related to ALK positive mutation. © Ivyspring International Publisher.
- Published
- 2016
4. Cardiotoxic effects of gemcitabin/cisplatin vs paclitaxel/carboplatin first-line chemotherapy in patients with advanced non-small cell lung cancer
- Author
-
Bursac, D.S., primary, Sarcev, T., additional, Velikic, D. Sazdanic, additional, and Tepavac, A., additional
- Published
- 2016
- Full Text
- View/download PDF
5. Advanced bronchoscopic techniques in diagnosis and staging of lung cancer
- Author
-
Zaric, B., Stojsic, V., Sarcev, T., Stojanovic, G., Carapic, V., Perin, B., Zarogoulidis, P., Darwiche, Kaid, Tsakiridis, K., Karapantzos, I., Kesisis, G., Kougioumtzi, I., Katsikogiannis, N., Machairiotis, N., Stylianaki, A., Foroulis, C. N., and Zarogoulidis, K.
- Subjects
Medizin - Published
- 2013
6. Neodymium yttrium-aluminium-garnet laser resection significantly improves quality of life in patients with malignant central airway obstruction due to lung cancer
- Author
-
Zaric, B., primary, Kovacevic, T., additional, Stojsic, V., additional, Sarcev, T., additional, Kocic, M., additional, Urosevic, M., additional, Kalem, D., additional, and Perin, B., additional
- Published
- 2014
- Full Text
- View/download PDF
7. 1199P - Cardiotoxic effects of gemcitabin/cisplatin vs paclitaxel/carboplatin first-line chemotherapy in patients with advanced non-small cell lung cancer
- Author
-
Bursac, D.S., Sarcev, T., Velikic, D. Sazdanic, and Tepavac, A.
- Published
- 2016
- Full Text
- View/download PDF
8. 4P CLINICO-PATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH LUNG ADENOCARCINOMA HARBOURING MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN THE SERBIAN POPULATION
- Author
-
Zaric, B., primary, Stojsic, V., additional, Carapic, V., additional, Tepavac, A., additional, Sarcev, T., additional, Jankovic, R., additional, and Perin, B., additional
- Published
- 2013
- Full Text
- View/download PDF
9. P-794 Evaluation of some prognostic factors in limited disease of smallcell lung cancer
- Author
-
Sarcev, T., primary, Perin, B., additional, Balaban, G., additional, Lalic, N., additional, Canak, V., additional, and Milovancev, A., additional
- Published
- 2005
- Full Text
- View/download PDF
10. Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study.
- Author
-
Bursac D, Petridis D, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Huang H, Bai C, Hohenforst-Schmidt W, Kosmidis C, Sapalidis K, Romanidis K, Courcoutsakis N, Lallas A, Tsakaldimis G, Chatzimichael K, Sardeli C, Matthaios D, Zarogoulidis P, and Karapantzou C
- Abstract
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms., Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded., Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect., Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions., Competing Interests: None to declare., (Copyright © 2014, Medical University Publishing House Craiova.)
- Published
- 2021
- Full Text
- View/download PDF
11. Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination.
- Author
-
Zarogoulidis P, Christakidis V, Petridis D, Sapalidis K, Kosmidis C, Vagionas A, Perdikouri EI, Hohenforst-Schmidt W, Huang H, Petanidis S, Tsakiridis K, Baka S, Romanidis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Boukovinas I, Tolis C, and Sardeli C
- Subjects
- B7-H1 Antigen, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Female, Humans, Prognosis, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Lung Neoplasms diagnostic imaging
- Abstract
Objectives : Lung cancer is still diagnosed at advanced stage and early treatment initiation is needed. Therefore, we need biomarkers or clusters of information that can provide early treatment prognosis. Methods : Biopsies were acquired from 471 patients-lung masses with CT-guided biopsy, convex probe transthorasic biopsy, and EBUS-TBNA convex probe with 18 G needles and 19 G needles. Results : Standardized uptake value (SUV) measurement is associated with female, smoking status, hepatic metastasis, adenocarcinoma and programmed death-ligand 1 (PD-L1). In specific we expect that SUV ≥ 7 is associated with PD-L1 ≥ 50. Conclusions : Lung masses indifferent of size that have SUV ≥ 7 will also have PD-L1 expression ≥ 50. Also, it is likely that these patients will be female with intense smoking habit and hepar or multiple metastasis.
- Published
- 2021
- Full Text
- View/download PDF
12. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
- Author
-
Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Zhou J, Wang Q, Wang X, Xia Y, Ding Y, Bai C, Kosmidis C, Sapalidis K, Sardeli C, Tsakiridis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Baka S, Athanasiou E, Hatzibougias D, Michalopoulou-Manoloutsiou E, Petanidis S, Drougas D, Drevelegas K, Paliouras D, Barbetakis N, Vagionas A, Freitag L, Lallas A, Boukovinas I, Petridis D, Ioannidis A, Matthaios D, Romanidis K, and Karapantzou C
- Abstract
Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients. Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Results: The relationships between changes of performance status and disease progression were examined via a single correspondence analysis. The two-dimensional scores (coordinates) derived from the correspondence analysis were then regressed against the predictors to form distinct splits and nodes obtaining quantitative results. The best fit is usually achieved by lowering exhaustively the AICc criterion and looking in parallel the change of R
2 expecting improvements more than 5%. both types of therapy are capable of producing best ameliorative effects, when either the programmed death-ligand-1 expression or parenchymal site in joint with low pack years are present in the sampling data. Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice. In specific for those with endobronchial lesions. Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2021
- Full Text
- View/download PDF
13. Thyroid cancer diagnosis with transdermal probe 22G U/S versus EBUS-convex probe TBNA-B 22G and 19G: pros and cons.
- Author
-
Zarogoulidis P, Huang H, Zhou J, Ning Y, Yang M, Wang J, Zhang R, Bai C, Shen X, Huang Z, Petridis D, Kosmidis C, Kosmidou M, Tsakiridis K, Hohenforst-Schmidt W, Baka S, Petanidis S, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Rapti A, Pantea S, Rogoveanu O, Rogoveanu I, Romanidis K, Kesisoglou I, Ioannidis A, Vagionas A, and Sapalidis K
- Subjects
- Analysis of Variance, Humans, Laryngeal Masks, Needles, Retrospective Studies, Endoscopic Ultrasound-Guided Fine Needle Aspiration methods, Thyroid Neoplasms diagnosis, Thyroid Neoplasms pathology
- Abstract
Introduction: Thyroid cancer is usually diagnosed both with imaging techniques and transdermal biopsy. Laboratory tests are also included in the initial work-up., Patients and Methods: One hundred and thirty patients were included in our study with pathological imaging findings in the thyroid region. Biopsies were performed with 22 G with transdermal convex probe, EBUS 22 G Mediglobe® needle and 19 G Olympus® needle. We investigated the efficiency and safety of both techniques and identified the best candidates for each method., Discussion: 19 G needle identified cancer types such as; Lymphoma, Medullary thyroid cancer, and Hurthle cell cancer, which we know from previous pathology studies that a larger sample is necessary for diagnosis. No safety issues were observed for both techniques and the EBUS technique produced more cell block material when 22 G needle was compared to transdermal biopsy in peritracheal lesions., Conclusion: The method of biopsy should be made based on the size and accessibility of the lesion.
- Published
- 2021
- Full Text
- View/download PDF
14. Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA.
- Author
-
Zarogoulidis P, Petridis D, Sapalidis K, Tsakiridis K, Baka S, Vagionas A, Hohenforst-Schmidt W, Freitag L, Huang H, Bai C, Drougas D, Theofilatou V, Romanidis K, Perdikouri EI, Petanidis S, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Perin B, Courcoutsakis N, Athanasiou E, Hatzibougias D, Drevelegas K, Boukovinas I, Kosmidou M, and Kosmidis C
- Abstract
Introduction: Novel technologies are currently used for lung cancer diagnosis. EBUS-TBNA 22G is considered one of the most important tools. However; there are still issues with the sample size. Patients and Methods: 223 patients underwent EBUS-TBNA with a 21G Olympus needle, 22GUS Mediglobe and 22GUB Mediglobe. In order to evaluate the efficiency of 22GUB novel needle design. In order to evaluate the sample size of each needle, we constructed cell blocks and measured the different number of slices from each biopsy site. Results: The 22GUB novel needle had similar and larger number of slices from each biopsy site compared to 21G needle. Discussion: Firstly as a novel methodology we used the number of slices from the constructed cell blocks in order to evaluate the sample size. Secondly, we should seek novel needle designs and not only concentrate on the volume of the sample size., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2020
- Full Text
- View/download PDF
15. The development of bronchoscopy in China: a national cross-sectional study.
- Author
-
Shi D, Li F, Wang K, Kong C, Huang H, Li Q, Jin F, Hu C, Wang C, Shi H, Hu Z, Dong Y, Ning Y, Tsakiridis K, Sapalidis K, Kosmidis C, Vagionas A, Hohenforst-Schmidt W, Freitag L, Turner JF, Drevelegas K, Perdikouri EI, Kovacevic T, Sarcev T, Zaric B, Petanidis S, Baka S, Boukovinas I, Kakolyris S, Zarogoulidis P, and Bai C
- Abstract
Objective: To investigate the development of bronchoscopy in China and compare it with its application in the early 21st century. Methods: The data collection was based on questionnaires. Three hundred and nineteen hospitals, which distributed across 30 provinces and 130 cities, were included in the study. Data about the application of bronchoscopy in Shanghai and Hunan province in the early 21st century are also involved for comparison. Results: The median period of performing diagnostic and therapeutic bronchoscopy was 19.7±11.0 and 7.4±7.0 years, respectively. On average, about 155.2 cases and 28.4 cases received diagnostic and therapeutic bronchoscopy in each hospital per month. The average area and number of the examination room was 122.7m
2 and 2.2m2 , respectively. More examination items were performed in specialty hospitals than those in general hospitals (P<0.05) and specialty hospitals owned more rooms exclusively for bronchoscopy (P<0.05), while no difference of the number of allocated doctors was found (P>0.05). On the other side, the whole amount of diagnosis and therapeutic items in teaching hospitals was slightly higher than that in non-teaching hospitals (P<0.01). Comparison of diagnosis and therapeutic endoscopy in Shanghai and Hunan province shows that the number of flexible bronchoscopy increased by 5.8 times in Shanghai from 2002 to 2017, while that increased by 3.4 times in Hunan province from 2005 to 2017. Furthermore, the average number of allocated doctors increased by 0.85 times in Shanghai, which was more rapidly compared with that of Hunan province (0.66 times) (P<0.05). Besides, the development rate of the diagnosis and therapeutic projects in Shanghai was significantly higher than that in Hunan province (P<0.05). Conclusion: All different classes of hospitals in China are capable of carrying out conventional bronchoscopy diagnosis and therapeutic projects, and newly developed bronchoscopy technology has gradually spread in high-level hospitals since 21st century. The higher class the hospital was, the earlier bronchoscopy was performed. Respiratory endoscopy in China has developed rapidly since the early 21st century and the construction of respiratory endoscopy center and the personnel training are on the right track, but it is also faced with inadequate equipment, unbalanced regional development and insufficient personnel allocation., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2020
- Full Text
- View/download PDF
16. Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population.
- Author
-
Zaric B, Stojsic V, Panjkovic M, Tegeltija D, Stepanov V, Kovacevic T, Sarcev T, Radosavljevic D, Milovancev A, Adamidis V, Zarogoulidis P, Hohenforst-Schmidt W, Trakada G, Rapti A, and Perin B
- Abstract
Introduction : The incidence of echinoderm microtubule-associated protein-like4-anaplastic lymphoma kinase (EML4-ALK) mutation among surgically treated patients with adenocarcinoma of the lung of the Eastern European ethnicity is underreported. The aim of this trial was the determination of EML4-ALK mutation frequency in investigated population, and the evaluation of correlations between lung adenocarcinoma subtype and clinical characteristics with mutation status. Patients and methods : This was a prospective trial which included 195 patients with adenocarcinoma of the lung who underwent surgical treatment. ALK mutation screening was performed by immunohistochemistry (IHC). IHC scores of 2+ and 3+ were regarded as positive. Confirmatory FISH was performed in all IHC positive and in 2:1 ratio in negative patients. Results : Overall ALK mutation rate established by IHC was 6.2%, while FISH confirmed rate of 5.1%. The FISH confirmed ALK positivity in 7.6% Hungarians, 5.5% Serbians, and 6.6% Slovakians. Acinar subtype of adenocarcinoma of the lung was significantly (p=0.02) related to EML4-ALK positive mutation status. Most of the patients were males (56.9%), smokers (50.8%), or former smokers (28.7%) with acinar (55.4%) or solid (35.9%) adenocarcinoma of the lung. Sensitivity and specificity of IHC were 100% and 98.9% respectively. Conclusions : ALK mutation rate in surgically treated patients with adenocarcinoma of the lung was found to be 6.2% by IHC and 5.1% by FISH. Acinar subtype of the adenocarcinoma of the lung was significantly related to ALK positive mutation., Competing Interests: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
- Published
- 2016
- Full Text
- View/download PDF
17. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma.
- Author
-
Zaric B, Stojsic V, Kovacevic T, Sarcev T, Tepavac A, Jankovic R, Spasic J, Radosavljevic D, Zarogoulidis P, Vukobradovic-Djoric N, and Perin B
- Subjects
- Adenocarcinoma epidemiology, Adenocarcinoma secondary, Adenocarcinoma of Lung, Adult, Aged, Bronchoscopy, DNA Mutational Analysis, Female, Follow-Up Studies, Humans, Lung Neoplasms epidemiology, Lung Neoplasms secondary, Lymphatic Metastasis, Male, Middle Aged, Polymerase Chain Reaction, Prospective Studies, Serbia epidemiology, Adenocarcinoma genetics, DNA, Neoplasm genetics, ErbB Receptors genetics, Lung Neoplasms genetics, Lymph Nodes pathology, Mutation Rate
- Abstract
Objective: Mutation rate in domain of EGFR gene varies between populations of lung cancer patients. Primary aim of this study was to analyze clinical and pathological characteristics, and tumor, node, metastasis status and stage of diseases, in relation to mutation status., Methods: After histological confirmation of lung adenocarcinoma tissue obtained during bronchoscopy was consecutively sent for EGFR testing. Genomic DNA extraction was performed with the QIAamp DNA FFPE Tissue kit. Clinical data for multivariate analysis were extracted from hospital based-lung cancer registry., Results: Among 360 tested patients, there was 67.8% males and 32.2% females, aged 61 ± 9.8 years. Majority of patients were smokers (57.0%) with Eastern Cooperative Oncology Group 1 performance status (92.2%). Mutation in EGFR gene was detected in 42 (11.7%) patients. Deletion in exon 19 was detected in 24 (6.7%) patients, mutation in exon 21 in 17 (4.7%), and mutation in exon 18 in one patient (0.3%). Patients were mostly diagnosed in stage IV adenocarcinoma (74.4%). Statistically significant differences were determined in relation to smoking (p < 0.001), T descriptor (size; p = 0.019) and gender (p = 0.002)., Conclusions: Mutation rate in domain of EGFR gene in investigated lung cancer population is in range with reported data in Caucasian race. Smoking, T descriptor and gender were found to be related to the EGFR status.
- Published
- 2014
- Full Text
- View/download PDF
18. Advanced bronchoscopic techniques in diagnosis and staging of lung cancer.
- Author
-
Zaric B, Stojsic V, Sarcev T, Stojanovic G, Carapic V, Perin B, Zarogoulidis P, Darwiche K, Tsakiridis K, Karapantzos I, Kesisis G, Kougioumtzi I, Katsikogiannis N, Machairiotis N, Stylianaki A, Foroulis CN, and Zarogoulidis K
- Abstract
The role of advanced brochoscopic diagnostic techniques in detection and staging of lung cancer has steeply increased in recent years. Bronchoscopic imaging techniques became widely available and easy to use. Technical improvement led to merging in technologies making autofluorescence or narrow band imaging incorporated into one bronchoscope. New tools, such as autofluorescence imagining (AFI), narrow band imaging (NBI) or fuji intelligent chromo endoscopy (FICE), found their place in respiratory endoscopy suites. Development of endobronchial ultrasound (EBUS) improved minimally invasive mediastinal staging and diagnosis of peripheral lung lesions. Linear EBUS proven to be complementary to mediastinoscopy. This technique is now available in almost all high volume centers performing bronchoscopy. Radial EBUS with mini-probes and guiding sheaths provides accurate diagnosis of peripheral pulmonary lesions. Combining EBUS guided procedures with rapid on site cytology (ROSE) increases diagnostic yield even more. Electromagnetic navigation technology (EMN) is also widely used for diagnosis of peripheral lesions. Future development will certainly lead to new improvements in technology and creation of new sophisticated tools for research in respiratory endoscopy. Broncho-microscopy, alveoloscopy, optical coherence tomography are some of the new research techniques emerging for rapid technological development.
- Published
- 2013
- Full Text
- View/download PDF
19. Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).
- Author
-
Zaric B, Stojsic V, Tepavac A, Sarcev T, Zarogoulidis P, Darwiche K, Tsakiridis K, Karapantzos I, Kesisis G, Kougioumtzi I, Katsikogiannis N, Machairiotis N, Stylianaki A, Foroulis CN, Zarogoulidis K, and Perin B
- Abstract
Lung cancer is one of the most common human malignancies and remains the leading cause of cancer related deaths worldwide. Many recent technological advances led to improved diagnostics and staging of lung cancer. With development of new treatment options such as targeted therapies there might be improvement in progression free survival of patients with advanced stage non-small cell lung cancer (NSCLC). Improvement in overall survival is still reserved for selected patients and selected treatments. One of the mostly investigated therapeutic options is adjuvant treatment. There are many open issues in selection of patients and administration of appropriate adjuvant treatment.
- Published
- 2013
- Full Text
- View/download PDF
20. Clinical prognostic factors and outcome of surgical treatment in patients with early-stage bronchial carcinoid tumors.
- Author
-
Stanic J, Zaric B, Anjelkovic A, Sarcev T, Eri Z, Boskovic T, and Perin B
- Subjects
- Bronchial Neoplasms mortality, Bronchial Neoplasms pathology, Carcinoid Tumor mortality, Carcinoid Tumor pathology, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Bronchial Neoplasms surgery, Carcinoid Tumor surgery
- Abstract
Purpose: Surgical resection is the treatment of choice for bronchial carcinoids (BC). The primary endpoint of this study was to look at the survival of patients with BC after the surgical treatment and to identify some clinicopathological prognostic factors influencing survival., Methods: The analysis included 57 patients with early- stage BC submitted to surgical treatment in the period 2000-2008. Major inclusion criteria were: pathologically confirmed BC, ECOG performance status 0-2, and surgical resection of the tumor., Results: No significant difference in survival in relation to gender was registered. N0, N1 and N2 status was registered in 39, 9 and 2 patients, respectively. There were statistically significant differences in survival according to N status (p=0.032). Twenty-two patients had T1N0 stage, 21 T2N0, and 4 T1N1. There was a trend for significant differences in survival according to TN stage (p=0.063). Also, analysis revealed significant differences in survival depending on tumor size (p=0.000), as well as on the type of the tumor (typical vs. atypical) (p=0.010)., Conclusion: Nodal status and TN stage affect patients' survival. Tumor size and typical/atypical tumor are also significant prognostic factors for survival of surgically treated patients.
- Published
- 2010
21. Autofluorescence videobronchoscopy (AFI) for the assessment of tumor extension in lung cancer.
- Author
-
Zaric B, Canak V, Stojanovic G, Jovelic A, Sarcev T, Kuruc V, Eri Z, Panjkovic M, and Milovancev A
- Subjects
- Adult, Aged, Female, Fluorescence, Humans, Lung Neoplasms pathology, Lung Neoplasms therapy, Male, Middle Aged, Prospective Studies, Video Recording, Bronchoscopy methods, Lung Neoplasms diagnosis
- Abstract
The major objective of our study was to determine the specificity and sensitivity of AFI videobronchoscopy vs. white light videobronchoscopy, in the assessment of lung cancer extent. Secondary objective was to investigate whether or not AFI can reveal greater extension of the tumor, and can it influence therapy making decision. Autofluorescence videobronchoscopy systems are new technology for visualization of bronchial mucosa, and the proper indications for such systems will be determined in the near future. In this prospective trial we have enrolled 27 patients with suspected lung cancer in whom we performed 108 diagnostic biopsies and 54 control biopsies. All patients underwent WL videobronchoscopy followed by Auto Fluorescence Imaging (AFI) examination of tracheobronchial tree. We were using videobronchoscope BF-F260 and EVIS LUCERA SPECTRUM processor unit. Overall specificity for AFI in the diagnostics of lung cancer was found to be 85%, sensitivity was 90%, positive predictive value (PPV) 78%, and negative predictive value (NPV) 94%. Specificity, sensitivity, PPV, and NPV for WL videobronchoscopy in lung cancer diagnostics were 54%, 64%, 51%, and 69%, respectively. Relative sensitivity ratio of AFI over WL videobronchoscopy, which is calculated to be 1.41, confirmed superiority of AFI in lung cancer diagnostics. We confirmed significant correlation between the greater extension of the tumor (assessed with AFI) and the therapeutical decision in lung cancer treatment (p = 0.01). Influence of AFI on therapeutical decision was significant (p = 0.034). AFI videobronchoscopy system yields significantly higher sensitivity and specificity for the assessment of lung cancer extent than WLB videobronchoscopy alone. It had shown to be able to influence therapeutic option for lung cancer treatment. Further studies are needed to evaluate and validate these results.
- Published
- 2009
- Full Text
- View/download PDF
22. [Influence of dexamethasone on appetite and body weight in lung cancer patients].
- Author
-
Sarcev T, Secen N, Sabo A, and Povazan D
- Subjects
- Dexamethasone adverse effects, Female, Glucocorticoids adverse effects, Humans, Male, Middle Aged, Appetite drug effects, Body Weight drug effects, Carcinoma, Bronchogenic drug therapy, Dexamethasone therapeutic use, Glucocorticoids therapeutic use, Lung Neoplasms drug therapy
- Abstract
Introduction: Anorexia and cachexia are the most common symptoms in cancer patients. They increase morbidity and mortality among cancer patients as well as complications of surgery, radiotherapy and chemotherapy. The most common drugs for treatment of cancer cachexia are corticosteroids and megestrol acetate., Material and Methods: The purpose of this study was to determine the influence of dexamethasone on appetite loss and weight loss in lung cancer patients treated with chemotherapy. Group A (30 patients) was treated with cisplatin, etoposide and standard supportive therapy, while group B (30 patients) received, in addition to this treatment, dexamethasone in the dose of 8 mg intravenously per day (1-3 day of chemotherapy)., Results: There was a statistically significant difference in appetite loss between two groups after the second chemotherapy cycle favouring group A. The analysis of weight loss showed a statistically significant difference between two groups after both chemotherapy cycles, once again in favour of group A. Concerning the impovement of appetite and weight gain, there was no statistically significant difference between two groups after both chemotherapy cycles., Discussion: Many double-blind randomized controlled studies showed beneficial symptomatic effect of corticosteroids in cancer cachexia, especially on the improvement of appetite, food intake and performance status. In most of the studies the weight gain was not recorded The most effective type of corticosteroids, dose and route of administration have not been established., Conclusion: Dexamethasone significantly decreases appetite loss and weight loss in lung cancer patients treated with chemotherapy, while it has no influence on appetite impovement and weight gain.
- Published
- 2008
- Full Text
- View/download PDF
23. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
- Author
-
Sarcev T, Secen N, Zaric B, and Milovancev A
- Subjects
- Aprepitant, Humans, Nausea chemically induced, Neoplasms drug therapy, Vomiting chemically induced, Antineoplastic Agents adverse effects, Morpholines therapeutic use, Nausea prevention & control, Neurokinin-1 Receptor Antagonists, Vomiting prevention & control
- Abstract
Despite progress in the area of supportive care in oncology in the last two decades, nausea and vomiting continue to be significant side effects of cancer therapy. These symptoms can escalate over time and can result in patients' refusal to continue with chemotherapy. Introduction of serotonin (5-HT3) receptor antagonists was a major therapeutic advance in the treatment of chemotherapy-induced nausea and vomiting with enhanced efficacy when corticosteroids were added. However, these agents have limited protection in the acute phase of chemotherapy-induced nausea and vomiting with little or no effect over the delayed phase. The aim of this review was to introduce a new class of antiemetics, a selective high-affinity antagonist at human substance P neurokinin 1 (NK(1)) receptors-aprepitant. Its pharmacological characteristics as well as its efficacy are reviewed. Aprepitant appears to be well tolerated but, due to its inhibitory effect on cytochrome P450 isoenzyme 3A4, it can lead to significant drug interactions, resulting in need for dose modification of concomitant therapy. The addition of aprepitant to 5-HT(3) receptor antagonists and corticosteroids was found to be superior to the combination of 5-HT(3) receptor antagonists and corticosteroids alone in patients treated with highly and moderately emetogenic chemotherapy. Clinical trials with aprepitant and other antiemetic agents are warranted to determine a regimen that will ensure complete protection from both acute and delayed chemotherapy-induced nausea and vomiting, thus contributing to improved supportive care and patients' quality of life (QoL).
- Published
- 2008
24. The effect of Nd:YAG laser resection on symptom control, time to progression and survival in lung cancer patients.
- Author
-
Zaric B, Canak V, Milovancev A, Jovanovic S, Budisin E, Sarcev T, and Nisevic V
- Subjects
- Aged, Brachytherapy, Combined Modality Therapy, Disease Progression, Female, Humans, Lung Neoplasms diagnosis, Lung Neoplasms radiotherapy, Male, Survival Analysis, Treatment Outcome, Lasers, Solid-State therapeutic use, Lung Neoplasms surgery
- Abstract
Purpose: The aim of this study was to determine the effect of Nd:YAG laser resection of centrally located tumors on the control of various symptoms and signs, time to progression and survival in lung cancer patients., Patients and Methods: We evaluated the effects of Nd: YAG laser resection in combination with high-dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT) vs. combination of HDR brachytherapy and EBRT alone on lung cancer symptoms and signs, ECOG performance status, time to progression and overall survival in lung cancer patients. Patients in group I (n=81) were treated with combination of HDR brachytherapy and EBRT, while patients in group II (n=97) were treated with Nd:YAG laser in combination with HDR brachytherapy and EBRT. Patients were evaluated before and after treatment, and were followed-up regularly every 3 months until the end of life. After RT +/- laser treatment all patients received standard chemotherapy (cisplatin plus etoposide) during the course of disease., Results: After treatment in both groups significant improvement in all investigated parameters was seen. Improvement in dyspnoea, thoracic pain, body weight loss and ECOG performance status was significantly better in group II (p <0.05), as were time to progression and overall survival (p <0.05)., Conclusion: Laser resection improves symptom control in lung cancer patients with central airway obstruction (CAO). Longer time to progression and survival of lung cancer patients could be the result of imminent airway desobstruction accomplished with Nd:YAG laser.
- Published
- 2007
25. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
- Author
-
Sarcev T, Secen N, Povazan Dj, Sabo A, Popovic J, Bursac D, Kakas M, Zaric B, and Milovancev A
- Subjects
- Aged, Antiemetics administration & dosage, Cisplatin administration & dosage, Cisplatin adverse effects, Dexamethasone administration & dosage, Drug Administration Schedule, Etoposide administration & dosage, Etoposide adverse effects, Female, Humans, Lung Neoplasms complications, Male, Metoclopramide administration & dosage, Metoclopramide therapeutic use, Middle Aged, Nausea chemically induced, Ondansetron administration & dosage, Ondansetron therapeutic use, Vomiting chemically induced, Antiemetics therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dexamethasone therapeutic use, Lung Neoplasms drug therapy, Nausea prevention & control, Vomiting prevention & control
- Abstract
Purpose: The aim of this study was to determine the influence of dexamethasone in the decrease of cisplatin and etoposide-induced nausea and vomiting in patients treated for lung cancer during and after 2 chemotherapy cycles., Patients and Methods: The analysis included 60 patients with histologically proven lung cancer, who were divided in two groups. Group A consisted of 30 patients who received cisplatin and etoposide with standard antiemetic drugs: ondansetron [serotonin receptor antagonist (5-HT(3) antagonist)] and metoclopramide (dopamine receptor antagonist). Group B consisted of 30 patients who received the same chemotherapy regimen with the previous antiemetic therapy plus dexamethasone 8 mg intravenously (i.v.) per day during the 3 days of chemotherapy. During and after the 3-day therapy, patients filled in a questionnaire issuing adverse effects of chemotherapy concerning many symptoms including nausea and vomiting. The results were statistically processed., Results: There was a significant decrease in the frequency and toxicity of nausea, acute and delayed vomiting in the group of patients who received antiemetic treatment with ondansetron, metoclopramide plus dexamethasone., Conclusion: Dexamethasone administered with 5-HT(3) antagonists and dopamine receptor antagonists significantly decreases the chemotherapy-induced nausea and vomiting.
- Published
- 2007
26. Interventional pulmonology techniques for immediate desobstruction of malignant central airway obstruction.
- Author
-
Zarić B, Canak V, Sarcev T, Marković M, Jovanović S, and Budisin E
- Subjects
- Airway Obstruction etiology, Argon, Electrocoagulation methods, Electrosurgery methods, Humans, Laser Coagulation methods, Lung Neoplasms pathology, Lung Neoplasms surgery, Neoplasm Invasiveness, Patient Selection, Practice Guidelines as Topic, Prosthesis Design, Pulmonary Surgical Procedures instrumentation, Stents, Airway Obstruction surgery, Lung Neoplasms complications, Pulmonary Surgical Procedures methods
- Abstract
In recent years interventional pulmonology techniques have found their place in the palliative treatment of lung cancer invading central airways (trachea and principal bronchi). The curative effect of interventional techniques is reported in a number of studies with very different success ratios, but with excellent potential and perspective. Increase in number and variety of these techniques led to the development of internationally accepted guidelines for their use. The choice of a specific interventional technique in the treatment of lung cancer patients with central airway obstruction (CAO) depends on several factors: patient's general condition and comorbidities, type and characteristics of airway stenosis, availability of techniques and trained personnel. The aim of this review was to introduce interventional pulmonology procedures aimed at urgent desobstruction of central airways obstruction to medical oncologists who are dealing with the problem of malignant CAO. We tried to emphasize indications, contraindications, technique procedure and possible complications in the treatment of malignant CAO. At the Institute for Pulmonary Diseases of Vojvodina Nd: YAG laser resection, electrocautery, argon plasma coagulation and metallic and silicone stent insertions for immediate treatment of malignant CAO are practised.
- Published
- 2007
27. Combination of interventional pulmonology techniques (Nd:YAG laser resection and brachytherapy) with external beam radiotherapy in the treatment of lung cancer patients with Karnofsky Index < or =50.
- Author
-
Canak V, Zarić B, Milovancev A, Jovanović S, Budisin E, Sarcev T, Lalić N, Nisević V, and Balaban G
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma radiotherapy, Adenocarcinoma surgery, Aged, Bronchial Neoplasms pathology, Bronchial Neoplasms radiotherapy, Bronchial Neoplasms surgery, Carcinoma, Large Cell pathology, Carcinoma, Large Cell radiotherapy, Carcinoma, Large Cell surgery, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Small Cell pathology, Carcinoma, Small Cell radiotherapy, Carcinoma, Small Cell surgery, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Combined Modality Therapy, Female, Humans, Karnofsky Performance Status, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Male, Middle Aged, Prospective Studies, Pulmonary Medicine, Survival Rate, Tracheal Neoplasms pathology, Tracheal Neoplasms radiotherapy, Tracheal Neoplasms surgery, Brachytherapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Laser Therapy
- Abstract
Purpose: To compare Nd: YAG laser resection with Nd: YAG laser plus brachytherapy and external beam radiotherapy (EBRT) in the palliation of malignant central airway obstruction symptoms due to lung cancer., Patients and Methods: In this prospective non-randomized study we evaluated the effects of Nd:YAG laser photoresection alone vs. Nd:YAG laser resection in combination with brachytherapy and EBRT on cough, dyspnoea, thoracic pain, haemoptysis, body weight loss, atelectasis, postobstructive pneumonia, endoscopic findings, disease-free period and survival rate in lung cancer patients. Only patients with Karnofsky index (KI) < or =50 were included. Sixty-four patients were divided into 2 groups: group I patients ( = 20) were treated only with Nd: YAG laser, and group II patients (n = 44) were treated with Nd: YAG laser followed by brachytherapy and EBRT., Results: Group I patients showed statistically significant improvement in all investigated parameters but cough. Group II patients achieved significant improvement in all investigated parameters. Comparative statistical analysis between the 2 groups revealed statistically significant improvement in group II with regard to dyspnoea, haemoptysis, KI and atelectasis. No significant improvement in group II was seen when other investigated parameters were considered. Disease-free period and survival rate were significantly longer in group II (p< or =0.0005)., Conclusion: The combination of interventional pulmonology procedures with standard modalities is the best option for the treatment of selected lung cancer patients.
- Published
- 2006
28. Bronchodilatation test response predictors in lung function assessment of patients with resectable lung cancer and concomitant chronic obstructive pulmonary disease.
- Author
-
Zarić B, Stanić J, Milovancev A, Canak V, Andjelić B, Sarcev T, and Kojicić M
- Subjects
- Aged, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Female, Humans, Lung Neoplasms complications, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, Pilot Projects, Preoperative Care, Pulmonary Disease, Chronic Obstructive complications, Respiratory Function Tests methods, Carcinoma, Non-Small-Cell Lung physiopathology, Lung Neoplasms physiopathology, Pulmonary Disease, Chronic Obstructive physiopathology
- Abstract
Purpose: The goal of this pilot study was to determine factors influencing the bronchodilatation test (BDT) response during preoperative lung function assessment in patients with resectable non-small cell lung cancer (NSCLC) and concomitant chronic obstructive pulmonary disease (COPD)., Patients and Methods: The analysis included 34 patients who met the following entry criteria: preoperative lung function assessment including a BDT, presence of operable, histologically confirmed stage IA-IIIA NSCLC established by computerized tomography (CT) and endoscopical findings, no more than one cardiovascular risk factor present, no interstitial pulmonary diseases (restriction exclusively due to the tumor), and patient's age up to 70 years. The study was partially retrospective and partially prospective. BDT was performed by forced expiratory volume in the first second (FEV1) measurement prior to and 30 min after two Berodual(R) inhalations (0.005 mg of fenoterol + 0.002 mg of ipratropium bromide per inhalation)., Results: Possible predictors of BDT response may include history of COPD longer than 15 years, N2 lymph nodes involvement, total lung restriction, and presence of a visible tumor in the main and intermediate bronchus., Conclusion: These possible predictors remain hypothetical as the study cohort is rather small, so a large scale research should follow to provide reliable data necessary to make definite conclusions.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.